NCT03095352
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Must have locally recurrent chest wall disease not amenable to surgical excision
Exclusions: Patients with known active central nervous system (CNS) metastases and/or leptomeningeal disease
https://ClinicalTrials.gov/show/NCT03095352